Atlas Trials

SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx

Clinical trial NCT06219980 · RECRUITING

Trial details

NCT number
NCT06219980
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
SBRT
Start date
2023-12-07
Primary completion
2025-12-07
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.